UK Stakeholder Perspectives on Surrogate Endpoints in Cancer, and the Potential for UK Real-World Datasets to Validate Their Use in Decision-Making

David Baldwin1 Department of Respiratory Medicine, Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham, UK

Jonathan Carmichael2 Department of Oncology, The National Institute for Health Research Leeds In Vitro Diagnostics Co-Operative (NIHR Leeds MIC), Leeds, UK

Gordon Cook3 Cancer Research UK Trials Unit, LICTR, University of Leeds & NIHR (Leeds) IVD MIC, Leeds, UK

Neal Navani4 Lungs for Living Research Centre, UCL Respiratory, University College London, London, UK;5 Department of Thoracic Medicine, University College London Hospital, London, UK

https://orcid.org/0000-0002-6412-7516

James Peach6 Human Centric Drug Discovery, Wood Centre for Innovation, Oxford, UKCorrespondence[email protected]

https://orcid.org/0009-0001-1065-0467

Ruth Slater7 Health Economics Unit, London, UK

Pete Wheatstone8 Patient and Public Involvement and Engagement Group, DATA-CAN, London, UK

Julia Wilkins7 Health Economics Unit, London, UK

Nicola Allen-Delingpole9 The Association of the British Pharmaceutical Industry, London, UK

Cicely EP Kerr10 Research Data Scotland, Bayes Centre, Edinburgh, UK

Khalid Siddiqui11 Janssen-Cilag Ltd, High Wycombe, UK

https://orcid.org/0000-0001-6448-0902

show all

UK Stakeholder Perspectives on Surrogate Endpoints in Cancer, and the Potential for UK Real-World Datasets to Validate Their Use in Decision-Making

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

UK Stakeholder Perspectives on Surrogate Endpoints in Cancer, and the Potential for UK Real-World Datasets to Validate Their Use in Decision-Making

Reprints and Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date